615253-61-7
|
|
|
- CAS号:
- 615253-61-7
- 英文名:
- SP187
- 英文别名:
- UV4);SP187;UV-4B;MON-?DNJ;SP-187,SP187;SP187 (MON-?DNJ;3,4,5-Piperidinetriol, 2-(hydroxymethyl)-1-(9-methoxynonyl)-, (2R,3R,4R,5S)-
- 中文名:
- 615253-61-7
- 中文别名:
- 化合物 T16914
- CBNumber:
- CB43339714
- 分子式:
- C16H33NO5
- 分子量:
- 319.44
- MOL File:
- 615253-61-7.mol
|
|
|
615253-61-7化学性质
-
沸点:
-
475.0±40.0 °C(Predicted)
-
|
-
密度:
-
1.128±0.06 g/cm3(Predicted)
-
|
-
储存条件:
-
Store at -20°C
-
|
-
溶解度:
-
Soluble in DMSO
-
|
-
酸度系数(pKa):
-
13.72±0.70(Predicted)
-
|
615253-61-7性质、用途与生产工艺
SP187 是一种靶向作用于宿主的针对丝状病毒感染的亚胺糖。SP187 在体内抗流感和登革热。
IC50: 29.97 μM (EBOV), 47.72 μM (MARV)
The antiviral activity of iminosugar SP187 (UV-4) in vitro against EBOV and MARV is assessed using a yield-plaque assay format and the IC
50
is determined. Antiviral activity for SP187 is observed with IC
50
of 29.97 and 47.72 μM for EBOV and MARV, respectively.
The efficacy of SP187 (UV-4), the active free base component of UV-4B, and UV-5, the most potent iminosugar tested in vitro, is first assessed using a mouse model of EBOV infection. In this study, C57Bl/6 mice are administered 10 or 100 mg/kg of SP187 or UV-5 via oral gavage or IP injection. Dosing started ~1h before infection with ~1000 pfu of mouse-adapted EBOV and is repeated BID for 10 days at approximately 12 hour intervals for UV-5 or TID at approximately 8 hour intervals for SP187. The selected doses and schedule are based on tolerability studies in naïve mice. No efficacy is observed in the iminosugar treated mice as compared to the vehicle control.
615253-61-7
上下游产品信息
上游原料
下游产品
| 更新日期 | 产品编号 | 产品名称 | CAS编号 | 包装 | 价格 |
|---|
| 2024/01/25 | HY-U00160 | 615253-61-7
SP187 | 615253-61-7 | 1mg | 3000元 |
| 2024/01/25 | HY-U00160 | 615253-61-7
SP187 | 615253-61-7 | 5mg | 6000元 |
615253-61-7, 615253-61-7 相关搜索:
- C16H33NO5
- 化合物 T16914
- 615253-61-7
- SP-187,SP187
- SP187 (MON-?DNJ
- UV4)
- MON-?DNJ
- UV-4B
- 3,4,5-Piperidinetriol, 2-(hydroxymethyl)-1-(9-methoxynonyl)-, (2R,3R,4R,5S)-
- SP187